🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 53635D202
- Market Cap
- Small Cap
- IPO
- 7/25/2018 · $11.00/share
- Previous Name
- Liquidia Technologies, Inc.
Business: Liquidia Corporation operates through the company’s subsidiaries, Liquidia Technologies, Inc. and RareGen. The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using its PRINT technology. RareGen provides commercialization for rare disease pharmaceutical products, such as Sandoz Inc.’s generic treprostinil for PAH.
Notes: November 18, 2020 - Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it has closed the previously announced acquisition of RareGen, LLC, reinforcing its commitment to patients and the pulmonary arterial hypertension (PAH) community. With the close of the merger transaction, Liquidia and RareGen have become wholly owned operating subsidiaries of Liquidia Corporation, which is expected to trade on the Nasdaq Capital Market under the ticker symbol “LQDA” on November 19, 2020 as the successor to Liquidia Technologies. Under the terms of the merger agreement, Liquidia Technologies stockholders will receive an identical number of shares of Liquidia Corporation common stock in exchange for their Liquidia Technologies common stock.
Company Contact
- CEO
- Roger Jeffs
- CFO
- Mike Kaseta
- Headquarters
- 419 Davis Drive, Suite 100, Morrisville, NC 27560
- Phone
- 919-328-4400
- Fax
- 919-328-4402
- Investor Relations
- Jason Adair · 919-328-4400 · jason.adair@liquidia.com